8th ASM Biodefense & Emerging Diseases Conference
For the third time in less than 2 years Pherecydes Pharma is presenting at a biofense conferences, in the USA.
Hôpital Robert Debré collaboration
On February 7th, 2010, Robert Debré Hospital (Paris-France) and Pherecydes Pharma signed an agreement to select bacteriophage variants for eradicating different Escherichia coli strains.
Perspectives
Nanotechnology and nanodevices
With the full control of T4 phage replication cycle and the possibility to introduce mutations and/or coding sequences as needed, without affecting the main phage functions, Pherecydes Pharma owns a biodevice with applications in nanotechnologies.
We are open to discuss potential collaborations for developing under contract or co-developing new nanodevices with applications in various fields.
With the full control of T4 phage replication cycle and the possibility to introduce mutations and/or coding sequences as needed, without affecting the main phage functions, Pherecydes Pharma owns a biodevice with applications in nanotechnologies.
We are open to discuss potential collaborations for developing under contract or co-developing new nanodevices with applications in various fields.
- Phage therapy biodrugs;
- Medical application diagnostic tools.